Soleno Therap 
Welcome,         Profile    Billing    Logout  
 1 Product   7 Diseases   1 Product   2 Trials   141 News 


12»
  • ||||||||||  Vykat XR (diazoxide choline controlled release) / Soleno Therap
    Enrollment closed:  Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome (clinicaltrials.gov) -  Apr 2, 2024   
    P3,  N=83, Active, not recruiting, 
    Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
  • ||||||||||  diazoxide choline controlled release (DCCR) / Soleno Therap, Imcivree (setmelanotide) / Rhythm Pharma
    Review, Journal:  Clinical Trials in Prader-Willi Syndrome: A Review. (Pubmed Central) -  Feb 12, 2023   
    The control of hyperphagia and improving food-related behaviors are the most important unmet needs in PWS and could be addressed with the development of a new therapeutic agent, as currently no approved therapeutics exist for PWS treatment. The status of clinical trials with existing results for the management of obesity and hyperphagia in PWS will be discussed in this review, including treatments such as beloranib, setmelanotide, a diazoxide choline controlled-release tablet (DCCR), an unacylated ghrelin analogue, oxytocin and related compounds, glucagon-like peptide 1 receptor agonists, surgical intervention, and transcranial direct-current stimulation.
  • ||||||||||  diazoxide choline controlled release (DCCR) / Soleno Therap
    Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome (ENDOExpo, Pod 5) -  Jul 16, 2022 - Abstract #ENDO2022ENDO_2812;    
    Learning Objective 1: Upon review of this abstract, learners will be able to summarize the long-term safety data of Diazoxide Choline Extended-Release (DCCR), a drug under development for treatment of hyperphagia in Prader-Willi syndrome (PWS). Science Topics for the Adipose Tissue - Appetite and Obesity : Central Regulation of Appetite and Feeding
  • ||||||||||  Vykat XR (diazoxide choline controlled release) / Soleno Therap
    Enrollment change, Trial withdrawal:  An Open-Label Study of DCCR Tablet in Patients With PWS (clinicaltrials.gov) -  Aug 18, 2021   
    P3,  N=0, Withdrawn, 
    Trial primary completion date: Apr 2021 --> Jun 2023 N=105 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  diazoxide choline controlled release (DCCR) / Soleno Therapeutics
    Journal:  Weighted discriminative collaborative competitive representation for robust image classification. (Pubmed Central) -  Sep 5, 2020   
    Furthermore, the robust WDCCR (R-WDCCR) is proposed with l-norm representation fidelity for recognizing noisy images. Extensive experiments on six image data sets demonstrate the effective and robust superiorities of the proposed WDCCR and R-WDCCR over the related state-of-the-art representation-based classification methods.
  • ||||||||||  diazoxide choline controlled release (DCCR) / Soleno Therapeutics
    [VIRTUAL] Motivators of inappropriate ovarian cancer screening: a survey of women and their clinicians (Online Day 2) -  Aug 18, 2020 - Abstract #MOGAASM2020MOGA_ASM_25;    
    Clinician knowledge and practice are discordant. Facilitators of OC screening encompass several behavioural domains and indicate the need for patient and clinician education and consideration of regulatory changes to reduce access to OC screening tests.
  • ||||||||||  Vykat XR (diazoxide choline controlled release) / Soleno Therap
    Trial completion:  A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome (clinicaltrials.gov) -  Jun 25, 2020   
    P3,  N=127, Completed, 
    Facilitators of OC screening encompass several behavioural domains and indicate the need for patient and clinician education and consideration of regulatory changes to reduce access to OC screening tests. Active, not recruiting --> Completed
  • ||||||||||  diazoxide choline controlled release (DCCR) / Soleno Therapeutics
    Journal:  Association of single nucleotide polymorphisms in TNFA and CCR5 genes with Japanese Encephalitis: A study from an endemic region of North India. (Pubmed Central) -  Jun 19, 2020   
    Higher frequency of TNFA rs1800629 G/A, CCR5 rs1799987 genotypes with A allele and lower frequency of combination lacking TNFA rs1800629 A, CCR5 rs333 Δ32, andCCR5 rs1799987 A alleles and CCL2 rs1024611 G/G genotype was observed in JE cases. TNFA rs1800629 A and CCR5 rs1799987 A alleles were associated with susceptibility while combination lacking TNFA rs1800629 A, CCR5 rs333 Δ32, and rs1799987 A alleles and CCL2 rs1024611 G/G genotype was associated with protection to JE.
  • ||||||||||  Vykat XR (diazoxide choline controlled release) / Soleno Therap
    Enrollment closed:  Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period (clinicaltrials.gov) -  Jun 18, 2020   
    P3,  N=105, Active, not recruiting, 
    TNFA rs1800629 A and CCR5 rs1799987 A alleles were associated with susceptibility while combination lacking TNFA rs1800629 A, CCR5 rs333 Δ32, and rs1799987 A alleles and CCL2 rs1024611 G/G genotype was associated with protection to JE. Recruiting --> Active, not recruiting
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  A Mechanism of Resistance to Antibody-Targeted Immune Attack. (Pubmed Central) -  Apr 10, 2020   
    We continuously exposed epidermal growth factor receptor (EGFR) A431 cells to KIR-deficient NK92-CD16V effector cells and the anti-EGFR cetuximab...Classic immune checkpoints did not modulate ADCC in this unique model system of immune resistance. We showed that the induction of ADCC resistance involves genetic and epigenetic changes that lead to a general loss of target cell adhesion properties that are required for the establishment of an immune synapse, killer cell activation, and target cell cytotoxicity.
  • ||||||||||  Vykat XR (diazoxide choline controlled release) / Soleno Therap
    Enrollment closed, Trial completion date, Trial primary completion date:  A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome (clinicaltrials.gov) -  Jan 13, 2020   
    P3,  N=105, Active, not recruiting, 
    If the results were replicated in a larger scale study, DCCR may be a preferred therapeutic option for patients with PWS. Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> May 2020 | Trial primary completion date: Dec 2019 --> May 2020
  • ||||||||||  Vykat XR (diazoxide choline controlled release) / Soleno Therap
    Trial completion date, Trial primary completion date:  Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period (clinicaltrials.gov) -  Dec 12, 2019   
    P3,  N=105, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> May 2020 | Trial primary completion date: Dec 2019 --> May 2020 Trial completion date: Feb 2020 --> Jun 2023 | Trial primary completion date: Dec 2019 --> Apr 2021
  • ||||||||||  diazoxide choline controlled release (DCCR) / Essentialis
    Journal:  Functional analysis by RNAi of an glutaredoxin gene in Helicoverpa armigera. (Pubmed Central) -  Sep 18, 2019   
    In addition, we found that HaGdccr knockdown enhanced the enzymatic activity of superoxide dismutase and the contents of hydrogen peroxide and ascorbate. Taken together, these results indicate that HaGdccr may play significant roles in protecting organisms against oxidative damage.
  • ||||||||||  diazoxide choline controlled release (DCCR) / Essentialis
    Biomarker, Journal:  The Correlation of KRAS Gene Expression and P53 Immunoexpression in Colorectal Adenocarcinoma. (Pubmed Central) -  Aug 14, 2019   
    This study concluded that KRAS and p53 mutations are involved in carcinogenesis, and the p53 mutation is a more dominant risk factor than KRAS mutation among West Java people. P53 mutations with diffuse pattern tend to express mutant KRAS while p53 negative and having a focal pattern tend to express wt KRAS.
  • ||||||||||  diazoxide choline controlled release (DCCR) / Essentialis
    Therapeutic and Recreational use of Amphetamines in Adolescence Have Opposite Neurodevelopmental Effects (Grand Ballroom Foyer) -  Jul 14, 2019 - Abstract #CADDRAADHD2019CADDRA_42;    
    Furthermore, high, but not low, drug doses downregulate the expression of the DCCreceptor ligand, Netrin-1, in the nucleus accumbens and prefrontal cortex...These results show that developmental consequences of exposure totherapeutic- versus abused-like doses of amphetamine in adolescence have dissimilar molecularsignatures, and opposite behavioral effects. These findings have important clinical relevance sinceamphetamines are widely used for therapeutic purposes in youth.
  • ||||||||||  Vykat XR (diazoxide choline controlled release) / Soleno Therap
    Trial completion date, Trial primary completion date:  A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome (clinicaltrials.gov) -  Jun 28, 2019   
    P3,  N=105, Recruiting, 
    These findings have important clinical relevance sinceamphetamines are widely used for therapeutic purposes in youth. Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019
  • ||||||||||  Vykat XR (diazoxide choline controlled release) / Soleno Therap
    Trial completion date, Trial primary completion date:  A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome (clinicaltrials.gov) -  Dec 31, 2018   
    P3,  N=105, Recruiting, 
    The diagnostic activity has increased among TS with other karyotypes than 45,X as well as among KS and Double Y. Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019
  • ||||||||||  Vykat XR (diazoxide choline controlled release) / Soleno Therap
    Enrollment change, Trial withdrawal:  Open-Label, Single- and Multiple-Dose Pharmacokinetic Study of Diazoxide Choline (clinicaltrials.gov) -  Sep 1, 2016   
    P1,  N=0, Withdrawn, 
    GTV dose ≥ 56 Gy and SIB technique were optimal approaches for radiotherapy. N=24 --> 0 | Not yet recruiting --> Withdrawn